**Table S7**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | | **Response (PD vs PR)** | |
|  | **binarization\*** | **AUC & IC95(AUC)** | **Fisher test p** |
| Figure 3A and 3B |  |  |  |
| ccrcc | ccrcc2+ccrcc3 vs ccrcc1+ccrcc4 | 0.78 [0.66 ; 0.9] | 0,0052 |
| ccrcc | ccrcc1+ccrcc2+ccrcc3 vs ccrcc4 | 0.64 [0.49 ; 0.8] | 0,0052 |
| Brannon | ccA+cluster3 vs ccB | 0.78 [0.66 ; 0.9] | 0,00553 |
| Table 1 |  |  |  |
| ccrcc | ccrcc2+ccrcc3 vs ccrcc1+ccrcc4 | 0.78 [0.66 ; 0.9] | 0,0052 |
| ccrcc | ccrcc1+ccrcc2+ccrcc3 vs ccrcc4 | 0.64 [0.49 ; 0.8] | 0,0052 |
| Neutrophils > 4500 mm3 | N vs Y | 0.71 [0.58 ; 0.84] |  |
| Sarcomatoid dedifferentiation |  | 0.67 [0.51 ; 0.84] |  |
| Heng | GOOD+INTERMEDIATE vs POOR | 0.7 [0.57 ; 0.83] |  |
| ECOG |  | 0.76 [0.64 ; 0.89] |  |
| Amp8q21.13 |  | 0.69 [0.56 ; 0.83] |  |
| Bone metastasis |  | 0.63 [0.5 ; 0.76] |  |
| Fuhrman grade diagnosis |  | 0.62 [0.51 ; 0.73] |  |
| MSKCC stage |  | 0.7 [0.57 ; 0.83] |  |
|  |  |  |  |
| **Variable** | | **Overall Survival** | |
|  | binarization\* | **Harrel C-index** | **logrank p** |
| Figure 3A and 3B |  |  |  |
| ccrcc | ccrcc2+ccrcc3 vs ccrcc1+ccrcc4 | 0.6 [0.48 ; 0.73] | 3,00E-04 |
| ccrcc | ccrcc1+ccrcc2+ccrcc3 vs ccrcc4 | 0.57 [0.47 ; 0.67] | 3,00E-04 |
| Brannon | ccA+cluster3 vs ccB | 0.6 [0.48 ; 0.73] | 0,0011 |
| Figure 3C: multivariate model for OS |  |  |  |
| ccrcc14\_vs\_23+metastasis\_bone+Amp8q21.13+sarcomatoid\_differentiation+MSKCC\_stage | | 0.76 [0.68 ; 0.85] | 0 |
| Table 1 |  |  |  |
| ccrcc | ccrcc2+ccrcc3 vs ccrcc1+ccrcc4 | 0.6 [0.48 ; 0.73] | 3,00E-04 |
| ccrcc | ccrcc1+ccrcc2+ccrcc3 vs ccrcc4 | 0.57 [0.47 ; 0.67] | 3,00E-04 |
| Neutrophils > 4500 mm3 | N vs Y | 0.58 [0.47 ; 0.7] |  |
| Sarcomatoid dedifferentiation |  | 0.43 [0.3 ; 0.57] |  |
| Heng | GOOD+INTERMEDIATE vs POOR | 0.57 [0.47 ; 0.68] |  |
| ECOG |  | 0.41 [0.28 ; 0.53] |  |
| Amp8q21.13 |  | 0.41 [0.29 ; 0.53] |  |
| Bone metastasis |  | 0.42 [0.31 ; 0.53] |  |
| Fuhrman grade diagnosis |  | 0.44 [0.32 ; 0.55] |  |
| MSKCC stage |  | 0.52 [0.41 ; 0.63] |  |
|  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | | **Progression Free Survival** | |
|  | binarization\* | **Harrel C-index** | **logrank p** |
| Figure 3A and 3B |  |  |  |
| ccrcc | ccrcc2+ccrcc3 vs ccrcc1+ccrcc4 | 0.58 [0.46 ; 0.71] | 0,001 |
| ccrcc | ccrcc1+ccrcc2+ccrcc3 vs ccrcc4 | 0.57 [0.47 ; 0.67] | 0,001 |
| Brannon | ccA+cluster3 vs ccB | 0.58 [0.46 ; 0.71] | 0,0142 |
| Figure 3C: multivariate model for PFS |  |  |  |
| ccrcc14\_vs\_23+ECOG+Amp8q21.13+sarcomatoid\_differentiation | | 0.74 [0.65 ; 0.83] | 0 |
| Table 1 |  |  |  |
| ccrcc | ccrcc2+ccrcc3 vs ccrcc1+ccrcc4 | 0.58 [0.46 ; 0.71] | 0,001 |
| ccrcc | ccrcc1+ccrcc2+ccrcc3 vs ccrcc4 | 0.57 [0.47 ; 0.67] | 0,001 |
| Neutrophils > 4500 mm3 | N vs Y | 0.63 [0.52 ; 0.73] |  |
| Sarcomatoid dedifferentiation |  | 0.44 [0.31 ; 0.57] |  |
| Heng | GOOD+INTERMEDIATE vs POOR | 0.58 [0.47 ; 0.69] |  |
| ECOG |  | 0.41 [0.3 ; 0.53] |  |
| Amp8q21.13 |  | 0.41 [0.29 ; 0.52] |  |
| Bone metastasis |  | 0.45 [0.34 ; 0.56] |  |
| Fuhrman grade diagnosis |  | 0.45 [0.34 ; 0.56] |  |
| MSKCC stage |  | 0.53 [0.42 ; 0.64] |  |
|  |  |  |  |
| \*: binarization used for AUC & C-Index | |  |  |

**Table S8**

  

**Table S9**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Sensitivity** | **Specificity** |
| **Ampl\_2p12** | **ccrcc4** | 0.73 | 0.72 |
| **Ampl\_2p22.3** | **ccrcc4** | 0.67 | 0.79 |
| **Ampl\_8q21.13** | **ccrcc4** | 0.80 | 0.67 |

**Table S10**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **ccrcc1** | **ccrcc2** | **ccrcc3** | **ccrcc4** |
| **Brannon et al. Classification** | **ccA** | -0.51 | 0.80 | 0.03 | -0.69 |
| **ccB** | 0.58 | -0.73 | -0.34 | 0.70 |
| **cluster\_3** | -0.04 | -0.3 | 0.61 | 0.12 |
| **TCGA subgroup prediction** | **ccrcc1** | 0.64 | -0.32 | -0.47 | 0.06 |
| **ccrcc2** | -0.45 | 0.73 | -0.09 | -0.56 |
| **ccrcc3** | 0.00 | -0.44 | 0.54 | 0.31 |
| **ccrcc4** | 0.49 | -0.53 | -0.32 | 0.52 |